The news is by your side.

Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) Drug Overview & Product Profiles 2016-2026

DUBLIN, July 12, 2019 /PRNewswire/ — The “Rituxan” report has been added to ResearchAndMarkets.com’s offering.

Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) is a murine/human chimeric cluster of differentiation (CD)20-targeted monoclonal antibody that is indicated for the treatment of a number of B-cell non-Hodgkin’s lymphomas and for rheumatoid arthritis patients who inadequately respond to anti-tumor necrosis factor therapy. Rituximab is marketed in the US by Roche’s Genentech subsidiary and Biogen under the Rituxan brand name. Outside the US, the drug is marketed by Roche as MabThera, and in Japan it is marketed by Chugai and Zenyaku Kogyo as Rituxan.

Despite failing to meet its primary endpoints in studies for systemic lupus erythematosus (SLE) patients, Rituxan continues to be considered an effective treatment option, specifically for those patients with more severe disease. The author believes that Rituxan will continue to be used off-label; however, reimbursement has become more difficult following the approval of Benlysta (belimumab; GlaxoSmithKline), and this is expected to become even more restrictive as additional therapies receive approval for use in SLE. The 2017 arrival of a biosimilar version of Rituxan in the EU further dampens Rituxan’s commercial attractiveness.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Off-label: Rituxan: Systemic lupus erythematosus (SLE)

Rituxan: Chronic lymphocytic leukemia (CLL)

Rituxan: NHL: Follicular lymphoma (FL)

Rituxan: NHL: Diffuse large B-cell lymphoma (DLBCL)

Rituxan: Rheumatoid arthritis (RA)

Rituxan: NHL: Mantle cell lymphoma (MCL)

LIST OF FIGURES

Figure 1: Rituxan for SLE – SWOT analysis

Figure 2: The authors drug assessment summary of Rituxan for SLE

Figure 3: Rituxan sales for SLE across the US and five major EU markets, by region, 2016-25

Figure 4: The authors drug assessment summary of Rituxan for CLL

Figure 5: Rituxan sales for CLL across the US, Japan, and five major EU markets, by country, 2017-26

Figure 6: Rituxan for follicular lymphoma – SWOT analysis

Figure 7: The authors drug assessment summary of Rituxan for follicular lymphoma

Figure 8: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 9: Rituxan for diffuse large B-cell lymphoma – SWOT analysis

Figure 10: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma

Figure 11: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 12: Rituxan for rheumatoid arthritis – SWOT analysis

Figure 13: The authors drug assessment summary of Rituxan in rheumatoid arthritis

Figure 14: Rituxan for mantle cell lymphoma – SWOT analysis

Figure 25: The authors drug assessment summary of Rituxan in mantle cell lymphoma

LIST OF TABLES

Table 1: Rituxan drug profile

Table 2: Rituxan pivotal trial data in SLE

Table 3: Rituxan sales for SLE across the US and five major EU markets, by region ($m), 2016-25

Table 4: Rituxan drug profile

Table 5: Approval history of Rituxan for CLL in the US, Japan, and five major EU markets

Table 6: Trials of Rituxan for CLL

Table 7: Rituxan for CLL – SWOT analysis

Table 8: Rituxan drug profile

Table 9: Rituxan pivotal trial data in follicular lymphoma

Table 10: Rituxan other clinical trial data in follicular lymphoma

Table 11: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 12: Rituxan drug profile

Table 13: Rituxan pivotal trial data in diffuse large B-cell lymphoma

Table 14: Rituxan Phase III data in diffuse large B-cell lymphoma

Table 15: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 16: Rituxan drug profile

Table 17: Rituxan pivotal trial data in rheumatoid arthritis

Table 18: Rituxan late-phase trial data in rheumatoid arthritis

Table 19: Rituxan drug profile

Table 20: Rituxan pivotal trial data in B-cell non-Hodgkin’s lymphoma

Table 21: Rituxan clinical studies in mantle cell lymphoma

For more information about this report visit https://www.researchandmarkets.com/r/fjx3cj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Comments are closed.